LFST · LifeStance Health Group, Inc.

LifeStance delivered a materially stronger-than-expected Q1 2026, marking a clear inflection point toward sustainable profitability. Revenue growth of 21% was underpinned by three interlocking drivers: an 11% year-over-year increase in clinician count (to 8,349), an 18% rise in visit volumes (to 2.5 million), and higher total revenue per visit — indicating both volume expansion and pricing or mix improvement. Income from operations jumped to $22.3 million from $1.6 million, while net income surged to $14.2 million from $0.7 million, reversing prior-year losses and confirming the scalability of its hybrid (virtual + in-person), tech-enabled, multidisciplinary clinician model. Margin expansion was broad-based: Center Margin grew 24% to $135.9 million (33.7% of revenue), and Adjusted EBITDA rose 48% to $51.1 million (12.7% of revenue), driven by improved operating leverage — specifically, revenue growing faster than general and administrative expenses and lower center costs as a percentage of revenue. Management attributed this to enhanced clinician productivity and disciplined cost management. Critically, the company raised full-year 2026 guidance across all key metrics, signaling confidence in continued execution: revenue now expected between $1.640–$1.680 billion (up from $1.615–$1.655 billion), Center Margin $547–$571 million (up from $526–$550 million), and Adjusted EBITDA $200–$220 million (up from $185–$205 million). The Q2 outlook further reinforces momentum, with revenue projected at $405–$425 million. These results validate LifeStance’s strategy of scaling through clinician recruitment, operational efficiency, and in-network reimbursement — all while maintaining clinical quality, as evidenced by its newly announced outcomes study showing clinically significant improvement for ~75% of ~180,000 patients. For investors, this represents not just top-line growth but a decisive shift toward durable, margin-accretive earnings power.